Study of VI-0521 Compared to Placebo in Treatment of Diabetes and Obesity in Adults With Obesity-Related Co-Morbid Conditions

Completed · Phase 3 · Has a placebo group

Conditions studied: Obesity, Type 2 Diabetes

In brief

The purpose of this study is to evaluate the efficacy and safety of VI0521 compared to placebo in treatment of obesity in an adult population with obesity related co-morbid conditions.

Key facts

Study ID

NCT00553787

Run by

VIVUS LLC

People needed

2487

Starts

2007-11-01

Expected to finish

2009-06-01

Last updated by the study team

2012-09-10

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Informed Consent
• BMI ≥ 27 (no lower BMI limit for Type 2 diabetics)
• 70 years of age or less
• Have 2 or more of the following obesity-related co-morbid conditions:
• Systolic blood pressure 140-160 mmHg (130-160 if diabetic);
• Diastolic blood pressure 90-100 mmHg (85-100 if diabetic);
• Requirement for 2 or more medications to achieve control (<140/90 mmHg)
• Triglyceride level between 200-400 mg/dL or requirement for 2 or more medications to achieve control (<200 mg/dL)
• At lease one of the following metabolic criteria:
• Fasting blood glucose level > 100 mg/dL
• Glucose level > 140 mg/dL
• Diagnosis of type 2 diabetes
• Waist circumference ≥ 102 cm for men or ≥88 cm for women

You may not qualify if…

• Stroke/MI/unstable cardiovascular disease within 6 months
• Clinically significant renal, hepatic or psychiatric disease
• Unstable thyroid disease or replacement therapy
• Nephrolithiasis
• Obesity of known genetic or endocrine origin
• Participation in a formal weight loss program or lifestyle intervention
• Glaucoma or intraocular pressure
• Pregnancy or breastfeeding
• Drug or Alcohol abuse
• Smoking cessation within previous 3 months or plans to quit smoking during study
• Eating disorders
• Cholelithiasis within past 6 months
• Excluded medications
• Type 1 diabetes or use of any antidiabetic medication other than metformin
• Previous bariatric surgery
• Bipolar disorder or psychosis
• Steroid hormone therapy
• Systolic blood pressure > 160 mmHg, diastolic blood pressure > 100 mmHg
• Creatinine clearance < 60 mL/minute

Where it is running

• Research Site — Birmingham, Alabama, United States
• Research Site — Ridgefield, Connecticut, United States
• Research Site — New York, New York, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Toledo, Ohio, United States
• Research Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.